$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

$bpth Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000114420413045992 Filed on August 14, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$810.0K	$240.0K	$250.0K
YoY Change	224.0%	-4.0%	-21.88%
% of Gross Profit
Research & Development	$568.6K	$156.0K	$190.0K
YoY Change	3.38%	-17.88%	35.71%
% of Gross Profit
Depreciation & Amortization	$40.00K	$40.00K	$50.00K
YoY Change	-20.0%	-20.0%	0.0%
% of Gross Profit
Operating Expenses	$1.394M	$428.6K	$787.8K
YoY Change	65.92%	-45.59%	69.87%
Operating Profit	-$1.394M	-$428.6K	-$787.8K
YoY Change		-45.59%	69.87%
Interest Expense	$0.00	$0.00	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$521.00	$1.402K	-$56.00
YoY Change		-2603.57%	-105.49%
Pretax Income	-$1.390M	-$430.0K	-$790.0K
YoY Change	65.48%	-45.57%	71.74%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.393M	-$427.2K	-$787.8K
YoY Change	65.86%	-45.77%	70.25%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.658M	-$1.303M	-$2.724M
COMMON SHARES
Basic Shares Outstanding	75.38M shares		58.87M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.100M	$1.930M	$160.0K
YoY Change	1142.42%	1106.25%	-86.89%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$200.0K	$46.41K	$46.49K
YoY Change	53.85%	-0.17%	-7.02%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.300M	$2.253M	$504.4K
YoY Change	834.78%	346.63%	-60.28%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles		$1.492M	$1.661M
YoY Change		-10.17%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.450M	$1.492M	$1.661M
YoY Change	-9.94%	-10.17%	-30.51%
TOTAL ASSETS
Total Short-Term Assets	$4.300M	$2.253M	$504.4K
Total Long-Term Assets	$1.450M	$1.492M	$1.661M
Total Assets	$5.750M	$3.745M	$2.165M
YoY Change	177.78%	72.95%	-40.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.00K	$165.9K	$31.15K
YoY Change	-42.86%	432.63%	55.74%
Accrued Expenses	$130.0K	$4.892K	$86.59K
YoY Change	-31.58%	-94.35%	-56.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$170.0K	$267.9K	$243.0K
YoY Change	-37.04%	10.22%	10.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$170.0K	$267.9K	$243.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$170.0K	$267.9K	$243.0K
YoY Change	-37.04%	10.22%	10.47%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$75.38K	$58.87K
YoY Change		28.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.580M	$3.477M	$1.922M
YoY Change
Total Liabilities & Shareholders Equity	$5.750M	$3.745M	$2.165M
YoY Change	177.78%	72.95%	-40.84%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$1.393M	-$427.2K	-$787.8K
YoY Change	65.86%	-45.77%	70.25%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$50.00K
YoY Change	-20.0%	-20.0%	0.0%
Cash From Operating Activities	-$720.0K	-$570.0K	-$630.0K
YoY Change	33.33%	-9.52%	142.31%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.880M	2.210M	210.0K
YoY Change	305.63%	952.38%	-70.83%
NET CHANGE
Cash From Operating Activities	-720.0K	-570.0K	-630.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	2.880M	2.210M	210.0K
Net Change In Cash	2.160M	1.640M	-420.0K
YoY Change	1170.59%	-490.48%	-193.33%
FREE CASH FLOW
Cash From Operating Activities	-$720.0K	-$570.0K	-$630.0K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$720.0K	-$570.0K	-$630.0K
YoY Change	33.33%	-9.52%	152.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Trading Symbol TradingSymbol	BPTH
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75380214	shares
	dei	Entity Registrant Name EntityRegistrantName	BIO-PATH HOLDINGS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001133818
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75380214	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62219050	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75380214	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62219050	shares
CY2012Q4	bpth	Common Stock Issuable Shares Issuable CommonStockIssuableSharesIssuable	2541700	shares
CY2013Q2	us-gaap	Cash Cash	1927226	USD
CY2012Q4	us-gaap	Cash Cash	534046	USD
CY2013Q2	us-gaap	Other Inventory OtherInventory	279180	USD
CY2012Q4	us-gaap	Other Inventory OtherInventory	195000	USD
CY2013Q2	us-gaap	Other Assets Current OtherAssetsCurrent	46411	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	42575	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	2252817	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	771621	USD
CY2013Q2	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2500374	USD
CY2012Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	2500374	USD
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1008544	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	928231	USD
CY2013Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1491830	USD
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1572143	USD
CY2013Q2	us-gaap	Assets Assets	3744647	USD
CY2012Q4	us-gaap	Assets Assets	2343764	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	165897	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	57000	USD
CY2013Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	10017	USD
CY2012Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	8582	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4892	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	137662	USD
CY2013Q2	bpth	Accrued Liabilities Related Parties Current AccruedLiabilitiesRelatedPartiesCurrent	37050	USD
CY2012Q4	bpth	Accrued Liabilities Related Parties Current AccruedLiabilitiesRelatedPartiesCurrent	26000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	742	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7539817	USD
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	787782	USD
CY2013Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	50000	USD
CY2012Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	100000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	267856	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	329244	USD
CY2013Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2013Q2	us-gaap	Liabilities Liabilities	267856	USD
CY2012Q4	us-gaap	Liabilities Liabilities	329244	USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	75380	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	62218	USD
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16615942	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13321075	USD
CY2013Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	0	USD
CY2012Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	762510	USD
CY2013Q2	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	13214531	USD
CY2012Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	12131283	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	3476791	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	2014520	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3744647	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2343764	USD
CY2013Q2	us-gaap	Revenues Revenues	0	USD
CY2012Q2	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	240543	USD
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	252168	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	480354	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	483482	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	428646	USD
	us-gaap	Operating Expenses OperatingExpenses	1084556	USD
	us-gaap	Operating Expenses OperatingExpenses	1310409	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-428646	USD
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-787782	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	78744	USD
CY2013Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
CY2012Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	244479	USD
CY2013Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	129	USD
CY2012Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	269	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	345	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	398	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	4518	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1402	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	34067	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3043311	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	84180	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	142477	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	279180	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3836	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	884710	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-884710	USD
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-56	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1310	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	344	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	318705	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-427244	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-787838	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1083246	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1310065	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13214531	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	66606105	shares
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58868713	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64412577	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	58625066	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47534377	shares
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	80312	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	96612	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	1057047	USD
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	USD
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	345000	USD
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	690000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	18500	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	318500	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29557	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1950	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	46411	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-61388	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-73108	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	267856	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1122781	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1029521	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8163408	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	435000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	15000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2515961	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	264709	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10555344	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2515961	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	264709	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10975344	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	1393180	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-789812	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	1927226	USD
CY2011Q4	us-gaap	Cash Cash	952252	USD
CY2007Q2	us-gaap	Cash Cash	0	USD
CY2012Q2	us-gaap	Cash Cash	162440	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	445	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	420000	USD
CY2011	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	345000	USD
CY2011	bpth	Percentage Of Change In Depreciation Amortization Of Intangible Assets And Asset Impairment And Other Charges Operating PercentageOfChangeInDepreciationAmortizationOfIntangibleAssetsAndAssetImpairmentAndOtherChargesOperating	0.5	pure
	bpth	Other Asset Impairment Charges Sirna License OtherAssetImpairmentChargesSirnaLicense	345000	USD
CY2013Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2500000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" style="clear:both;width:100%; table-layout:fixed;"> <tr> <td></td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="clear:both;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><strong>1.</strong></div> </td> <td> <div><strong>Organization and Business</strong></div> </td> </tr> </table> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2"> </font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, recently in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial will be tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data that will demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m<sup>2</sup>. However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company was proceeding with requesting the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors, advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose 60 mg/m<sup>2</sup>, which had been increased from 50 mg/m<sup>2</sup>in the revised protocol. The Company has enrolled three patients in Cohort 6 for treatment at a dose of 90 mg/m<sup>2</sup>.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Principal Investigator for the Phase I clinical trial, Jorge Cortes, M.D., is a leading expert in the treatment of CML, AML, MDS and ALL. Because the results of the first trial produced unexpected and clinically interesting results in some patients, the Principal Investigator prepared an abstract of the results of the first cohort that was accepted for presentation at the American Society of Hematology annual meeting in December of 2011. Results that demonstrated potential anti-leukemia benefits in treated patients were included in the presentation. The Principal Investigator is currently preparing an abstract of updated information for presentation at the American Society of Hematology annual meeting in December of 2013.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In this regard, in August of 2013 Bio-Path made a major announcement that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Phase I clinical trial is typically ended when a maximum tolerated dose (MTD) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the end of January 2012, the Company’s Board of Directors held a strategic planning session. Among several topics was a discussion of Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $<font style=" FONT-SIZE: 10pt">345,000</font> at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (<font style=" FONT-SIZE: 10pt">50</font>%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $<font style=" FONT-SIZE: 10pt">345,000</font>, and cancel the license.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path has become a publicly traded company (symbol OTCBB: BPTH) as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An important milestone was achieved for the Company in the second quarter, 2012 when Bio-Path’s common stock began trading on the quality-controlled OTCQX. OTCQX is the highest tier, premier trading platform for OTC companies. The Company also announced that it had retained Roth Capital Partners to serve as the Company’s Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for providing guidance on OTCQX requirements.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As of June 30, 2013, Bio-Path had $<font style=" FONT-SIZE: 10pt">1,927,226</font> in cash on hand. During the second quarter of 2013, the Company received approximately $<font style=" FONT-SIZE: 10pt">2.5</font> million in cash from the sale of shares of common stock in a private placement and direct offering that have both been closed. The Company has since opened a new private placement in the second quarter of 2013 with the goal of raising up to $<font style=" FONT-SIZE: 10pt">4</font> million from the sales of shares of its common stock. Bio-Path plans to begin raising significant amounts of additional development capital at anticipated higher share prices once there is demonstration of proof-of-concept of Bio-Path’s technology in human patients.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.</div> </div>
CY2013Q2	bpth	Proceeds From Issuance Of Private Placement Two ProceedsFromIssuanceOfPrivatePlacementTwo	4000000	USD
CY2013Q2	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	165897	USD
CY2012Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	57000	USD
CY2013Q2	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	114200	USD
CY2013Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	6800	USD
CY2013Q2	bpth	Accounts Payable To Public Filing Services AccountsPayableToPublicFilingServices	6000	USD
CY2013Q2	bpth	Accounts Payable To Professional Fees Current AccountsPayableToProfessionalFeesCurrent	15900	USD
CY2008Q2	bpth	Fair Value Of Common Stock Issued FairValueOfCommonStockIssued	180000	USD
CY2008Q2	bpth	Common Stock Additional Shares Issued CommonStockAdditionalSharesIssued	24	shares
CY2011Q4	bpth	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	1920000	shares
CY2011Q4	bpth	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	576000	USD
CY2012Q3	bpth	Stock Issued During Period Shares Contingent Considerations StockIssuedDuringPeriodSharesContingentConsiderations	50000	shares
CY2012Q3	bpth	Issuance Of Common Stock Shares For Service IssuanceOfCommonStockSharesForService	18500	shares
CY2012Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	795001	USD
CY2012Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	708600	USD
CY2013Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	346201	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	25000	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.54
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	1.75	pure
CY2013Q2	bpth	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue	12975	USD
CY2013Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	13538	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2013Q2	bpth	Accrued Liabilities Related Party Current AccruedLiabilitiesRelatedPartyCurrent	37050	USD
	us-gaap	Cost Of Reimbursable Expense CostOfReimbursableExpense	75000	USD
CY2013Q2	bpth	Accrued Patent Expense Current AccruedPatentExpenseCurrent	25000	USD
	bpth	Drug Product Testing Agreement Consideration To Be Paid In Stages DrugProductTestingAgreementConsiderationToBePaidInStages	340000	USD
	bpth	Drug Product Estimated Cost DrugProductEstimatedCost	165000	USD
CY2012Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4000000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, “Bio-Path” or the “Company”) as of and for the fiscal year ended December 31, 2012. The results of operations for the period ended June 30, 2013, are not necessarily indicative of the results for a full-year period.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div>

Files In Submission

Name	View Source	Status
0001144204-13-045992-index-headers.html	Edgar Link	pending
0001144204-13-045992-index.html	Edgar Link	pending
0001144204-13-045992.txt	Edgar Link	pending
0001144204-13-045992-xbrl.zip	Edgar Link	pending
bpth-20130630.xml	Edgar Link	completed
bpth-20130630.xsd	Edgar Link	pending
bpth-20130630_cal.xml	Edgar Link	unprocessable
bpth-20130630_def.xml	Edgar Link	unprocessable
bpth-20130630_lab.xml	Edgar Link	unprocessable
bpth-20130630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v352628_10q.htm	Edgar Link	pending
v352628_ex10-1.htm	Edgar Link	pending
v352628_ex31.htm	Edgar Link	pending
v352628_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth

2013 Q3 Form 10-Q Financial Statement

#000114420413045992 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH BIO-PATH HOLDINGS, INC. Stock $bpth

2013 Q3 Form 10-Q Financial Statement

#000114420413045992 Filed on August 14, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BPTH
BIO-PATH HOLDINGS, INC. Stock $bpth